US FDA grants accelerated approval to Rubraca
Rubraca is a poly ADP-ribose polymerase (PARP) inhibitor to treat women with a certain type of ovarian cancer
Author
Withdraw nod for 28 drug applications of Ranbaxy: Sun Pharma
In April 2014, Sun Pharma had announced the acquisition of the troubled rival Ranbaxy in an all-stock transaction worth $4 billion
Cipla receives final approval for Generic Tricor tabs
Fenofibrate tabs will be available for commercial shipment in the US in the coming weeks
Domestic sales to drive demand in next three to five years: UBM India survey
The main risk factor recognised by the international respondents is the over-dependence on Chinese sourced APIs, particularly in…
Drug companies bet on global M&As in growth pursuit: Moody’s
The report also mentioned that M&As can also enhance the expertise of Indian pharma companies in sophisticated and high-entry…
Lupin receives US FDA approval for generic Topicort ointment
The ointment is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Sun Pharma, Moebius Medical in global licensing deal
To develop novel liposomal non-opiod pain product for osteoarthritis
Sun Pharma launches first branded ophthalmic product in the US
BromSite will be marketed by Sun Ophthalmics
CII appreciates FSSAI’s operationalisation of nutraceutical regulation
The regulation will help resolve issues confronting the sector and create a conducive regulatory environment for the industry to…
Lincoln Pharma delists from Ahmedabad Stock Exchange
The Ahmedabad-based company, however, remains listed on the BSE and NSE